Benefits
Muscle protein synthesis and recovery acceleration
PeptiStrong® is clinically demonstrated to improve muscle protein synthesis rates and accelerate recovery from exercise-induced muscle damage. The AI-identified peptide network simultaneously activates mTORC1 (anabolic pathway) and modulates myostatin (catabolic brake) — a combination that produces faster, more complete muscle recovery between training sessions than either mechanism alone.
Strength and muscle performance
Three human RCTs confirm PeptiStrong® significantly improves muscle strength, particularly lower body strength, vs. placebo. The 2.4g dose produces meaningful strength gains comparable to the DL-185® dileucine clinical data — establishing PeptiStrong® alongside dileucine as one of the most evidence-backed novel muscle-building ingredients available.
Protein utilization efficiency
PeptiStrong® improves the body's ability to utilize dietary protein for muscle building — increasing muscle protein synthesis per gram of protein consumed. This means athletes using PeptiStrong® get more anabolic value from their existing protein intake, relevant for both performance maximization and for aging populations where protein utilization efficiency declines (anabolic resistance).
Endurance and exercise capacity
A third clinical study confirmed PeptiStrong® benefits extend to endurance performance — improving time to exhaustion and exercise capacity markers. This breadth of evidence (recovery, strength, protein utilization, endurance) positions PeptiStrong® as a comprehensive performance ingredient beyond niche muscle-building applications.
Mechanism of action
AI-identified peptide mTORC1 activation and myostatin inhibition
Nuritas' Magnifier AI platform analyzed thousands of fava bean protein sequences against proteomics databases to identify peptide sequences with predicted mTORC1 activating and myostatin-binding properties. The identified peptides activate mTORC1/p70S6K signaling (triggering muscle protein synthesis initiation) while simultaneously binding and partially blocking myostatin — the TGF-β family member that limits muscle growth. This dual mechanism amplifies the anabolic response to exercise beyond what leucine or EAA supplementation achieves alone.
Clinical trials
Randomized, double-blind, placebo-controlled trial of PeptiStrong® (2,400 mg/day fava bean peptides) effects on recovery from exercise-induced muscle damage. Outcomes: CK, range of motion, strength recovery. (2022, Front Nutr)
Trained adults post-exercise.
PeptiStrong® accelerated recovery from exercise-induced muscle damage, reduced CK elevation, improved range of motion vs placebo. Industry-funded (Nuritas). Effect sizes modest. Note: PeptiStrong® was 'discovered' using AI-driven peptide screening from fava beans — novel discovery approach.
Randomized, double-blind, placebo-controlled trial examining PeptiStrong® effects on muscle protein synthesis from dietary protein and protein utilization. (2022, J Int Soc Sports Nutr)
Active adults.
PeptiStrong® modestly improved MPS stimulation from dietary protein vs placebo. Industry-funded. Note: small evidence base; the AI-discovery framing is novel marketing but the underlying clinical evidence is modest. Whey protein has decades of stronger MPS evidence.